Tim Kelly, PhD, named President, Manufacturing at AskBio.
Tim Kelly Joins AskBio as President of Manufacturing to Lead AAV Vector Production for Gene Therapy
12 mars 2020 09h11 HE | Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., March 12, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio-Logo.jpg
CYTOO and AskBio Enter Research Agreement to Screen Gene Therapy Candidates for Rare Muscle Disorder
02 mars 2020 13h21 HE | Asklepios BioPharmaceutical, Inc.
GRENOBLE, France and RESEARCH TRIANGLE PARK, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- CYTOO, a leading drug discovery company on muscle disorders, today announced that it has entered into a research...
AskBio-Logo-horizontal with-Tagline.jpg
AskBio Appoints Anna Tretiakova, PhD, as Senior Vice President of Product Development
19 févr. 2020 09h18 HE | Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio-Logo-horizontal with-Tagline.jpg
AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure
04 févr. 2020 08h05 HE | Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, and its NanoCor...
AskBio-Logo-with-NoTagline_Black_Large.png
AskBio to Present at the 38th Annual J.P. Morgan Healthcare Conference
02 janv. 2020 16h53 HE | Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a fully integrated, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
AskBio-Logo-with-NoTagline_Black_Large.png
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
19 déc. 2019 08h25 HE | Asklepios BioPharmaceutical, Inc.
– Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and...